TY - JOUR
T1 - Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma
T2 - A prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)
AU - Tucci, Alessandra
AU - Martelli, Maurizio
AU - Rigacci, Luigi
AU - Riccomagno, Paola
AU - Cabras, Maria Giuseppina
AU - Salvi, Flavia
AU - Stelitano, Caterina
AU - Fabbri, Alberto
AU - Storti, Sergio
AU - Fogazzi, Stefano
AU - Mancuso, Salvatrice
AU - Brugiatelli, Maura
AU - Fama, Angelo
AU - Paesano, Paolo
AU - Puccini, Benedetta
AU - Bottelli, Chiara
AU - Dalceggio, Daniela
AU - Bertagna, Francesco
AU - Rossi, Giuseppe
AU - Spina, Michele
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Abstract We performed a multicenter study to validate the concept that a simple comprehensive geriatric assessment (CGA) can identify elderly, non-fit patients with diffuse large B-cell lymphoma (DLBCL) in whom curative treatment is not better then palliation, and to analyze potential benefits of treatment modulation after further subdividing the non-fit category by CGA criteria. One hundred and seventy-three patients aged > 69 treated with curative or palliative intent by clinical judgement only were grouped according to CGA into fit (46%), unfit (16%) and frail (38%) categories. Two-year overall survival (OS) was significantly better in fit than in non-fit patients (84% vs. 47%; p <0.0001). Survival in unfit and frail patients was not significantly different. Curative treatment slightly improved 2-year OS in unfit (75% vs. 45%) but not in frail patients (44% vs. 39%). CGA was confirmed as very efficient in identifying elderly patients with DLBCL who can benefit from a curative approach. Further efforts are needed to better tailor therapies in non-fit patients.
AB - Abstract We performed a multicenter study to validate the concept that a simple comprehensive geriatric assessment (CGA) can identify elderly, non-fit patients with diffuse large B-cell lymphoma (DLBCL) in whom curative treatment is not better then palliation, and to analyze potential benefits of treatment modulation after further subdividing the non-fit category by CGA criteria. One hundred and seventy-three patients aged > 69 treated with curative or palliative intent by clinical judgement only were grouped according to CGA into fit (46%), unfit (16%) and frail (38%) categories. Two-year overall survival (OS) was significantly better in fit than in non-fit patients (84% vs. 47%; p <0.0001). Survival in unfit and frail patients was not significantly different. Curative treatment slightly improved 2-year OS in unfit (75% vs. 45%) but not in frail patients (44% vs. 39%). CGA was confirmed as very efficient in identifying elderly patients with DLBCL who can benefit from a curative approach. Further efforts are needed to better tailor therapies in non-fit patients.
KW - Chemotherapeutic approaches
KW - Immunotherapy
KW - Lymphoma and Hodgkin disease
UR - http://www.scopus.com/inward/record.url?scp=84929083288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929083288&partnerID=8YFLogxK
U2 - 10.3109/10428194.2014.953142
DO - 10.3109/10428194.2014.953142
M3 - Article
C2 - 25110825
AN - SCOPUS:84929083288
SN - 1042-8194
VL - 56
SP - 921
EP - 926
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -